Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC) Meeting Abstract

  

Authors:	Meric-Bernstam, F.; Tannir, N. M.; Mier, J. W.; DeMichele, A.; Telli, M. L.; Fan, A. C.; Munster, P. N.; Carvajal, R. D.; Orford, K. W.; Bennett, M. K.; Iliopoulos, O.; Owonikoko, T. K.; Patel, M. R.; McKay, R.; Infante, J. R.; Voss, M. H.; Harding, J. J.
Abstract Title:	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	261s
Language:	English
ACCESSION:	WOS:000404665407141
DOI:	10.1200/JCO.2016.34.15_suppl.4568
PROVIDER:	wos
Notes:	Meeting Abstract: 4568 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155027